Similarly, HER2-expressing ESCC tumour cells were efficiently killed by Trastuzumab-mediated ADCC, with PBMCs derived from patients and healthy donors, and the ADCC activity reflected the degree of HER2 expression, as shown in Figure 1B (high HER-2-expressing TE4 vs low HER-2-expressing KYSE50). This evidence concerns the gene ERBB2 and neoplasm.